How Much Muscle You'll Lose on Retatrutide (TRIUMPH-1 Data)

Eli Lilly dropped the TRIUMPH-1 topline on May 21, 2026, and the headline number is brutal: 28.3% mean body weight loss at 80 weeks on 12mg retatrutide, climbing to 30.3% by week 104 in the heavier subgroup. The press wrote it up as bariatric-level weight loss in a syringe. None of the coverage answered the question every lean athlete actually wants answered: how much of that was muscle.

What TRIUMPH-1 actually measured

TRIUMPH-1 randomised 2,339 adults with obesity (BMI ≥30, or ≥27 with a comorbidity) to weekly subcutaneous retatrutide at 4mg, 9mg, or 12mg versus placebo. The escalation started at 2mg and stepped up every 4 weeks. Primary endpoint was percent weight change from baseline at week 80, with a 24-week extension to week 104 restricted to participants with baseline BMI ≥35.

Baseline weight averaged around 248lbs at a mean BMI near 40. Type 2 diabetes was excluded, which matters because GLP-1 efficacy is generally higher in non-diabetic obese subjects than in T2D cohorts.

The week 80 numbers (Eli Lilly, 2026):

• 12mg: −28.3% (about −70.3lbs)
• 9mg: −25.9% (about −64.4lbs)
• 4mg: −19.0% (about −47.2lbs)
• Placebo: −2.2% (about −5.5lbs)

The 104-week extension in the BMI ≥35 group pushed 12mg to −30.3% with no plateau visible. Responder rates at 12mg were also remarkable: 62.5% hit at least 25% weight loss, 45.3% lost at least 30%, and 27.2% lost at least 35%. Sixty-five percent of the 12mg arm crossed below BMI 30 by week 80.

Discontinuation due to adverse events tracked closely with dose: 4.1% on 4mg, 6.9% on 9mg, 11.3% on 12mg, versus 4.9% on placebo. The 12mg arm dropped out at more than double the placebo rate, mostly for GI tolerability and the dysesthesia signal covered below.

For context, the 24.2% weight loss reported in the Phase 2 trial at 12mg over 48 weeks (Jastreboff et al., 2023) turned out to underestimate the Phase 3 ceiling. Lilly bumped the trial duration from 48 to 80+ weeks and got an extra 4 to 6 percentage points of weight loss because the curve hadn't flattened in Phase 2.

How much of that was muscle?

This is the question Lilly's press release didn't answer, and it won't be answered for a while. TRIUMPH-1 did not publish a DEXA body composition substudy in the topline release, and based on the trial registry there is no dedicated body comp arm of comparable size to what SURMOUNT-1 ran for tirzepatide.

The closest retatrutide-specific body composition data comes from a separate Phase 2 substudy in type 2 diabetes (Coskun et al., 2025). At 36 weeks with N=103:

• Fat mass dropped 26.1% on 8mg and 23.2% on 12mg
• The authors stated lean mass loss proportional to total weight loss was "similar to other obesity treatments"

That phrase, "similar to other obesity treatments," is doing a lot of heavy lifting. The benchmark to compare against is SURMOUNT-1's tirzepatide DEXA substudy (Look et al., 2025), N=160 at week 72:

• Total weight: −21.3%
• Fat mass: −33.9% (about −16kg)
• Lean mass: −10.9% (about −5.6kg)
• Ratio of lean to total loss: about 25%

STEP-1 (semaglutide 2.4mg) showed a similar pattern in its body composition exploratory analysis (Wilding et al., 2021 STEP-1 J Endocr Soc): lean mass dropped 9.7% over 68 weeks, but the proportion of lean mass relative to total body mass actually increased by 3 percentage points because fat dropped faster.

The 75/25 rule (and why it underestimates muscle loss for you)

The pattern across the GLP-1 / GIP / glucagon class is roughly 75% of weight lost comes from fat, 25% from lean tissue. This sounds reassuring until you understand two things.

First, DEXA's "lean mass" compartment includes water, glycogen, intramuscular triglyceride, connective tissue, and visceral organ mass. It is not the same as skeletal muscle. The gold standard for true muscle mass is D3-creatine dilution, which has never been used in any retatrutide, tirzepatide, or semaglutide trial. So even the 25% lean loss figure almost certainly overstates pure muscle loss in obese subjects, where a chunk of that "lean" loss is hepatic glycogen and the visceral fat-pad-related water that comes off with metabolic improvement.

Second, the 75/25 rule was measured in subjects averaging BMI 35 to 40. They walked in with 100 to 130lbs of fat to mobilise. When the body is asked to lose 56lbs of total mass and only 24lbs of fat is physiologically accessible (the case for a 200lb athlete at 12% body fat), the deficit has to come from somewhere. Lean mass loss almost certainly disproportionately hits skeletal muscle when there isn't excess fat to spare.

What 28.3% means for a lean athlete

The honest math for a 200lb athlete at 12% body fat:

• Total fat mass at baseline: 24lbs
• Total lean mass (including everything else): 176lbs
• 28% body weight loss: 56lbs
• If all 24lbs of fat is mobilised, that still leaves 32lbs of lean mass to lose
• 32lbs out of 176lbs lean = 18% lean mass loss

Compare that to SURMOUNT-1's 10.9% lean mass loss in obese subjects who had abundant fat to draw on. The structural mismatch between trial population and lean athlete population means TRIUMPH-1 efficacy numbers don't translate. Nobody at 12% body fat should be targeting 28% weight loss on retatrutide. That goal would liquidate your physique.

Translating an 80-week obesity trial to a 16-week cut

Most enhanced athletes don't run retatrutide for 80 weeks. The common use case is a 12 to 20 week pre-contest or summer cut, often stacked on top of TRT and sometimes a low-dose anabolic compound for muscle preservation. The first thing TRIUMPH-1 tells you is that weight loss compounds over time. The week 80 number wasn't reached at week 16. Looking at the Phase 2 weight curve (Jastreboff et al., 2023), most subjects had lost roughly 50 to 60% of their eventual peak loss by week 24, and only about 30 to 40% of total peak loss by week 16.

For a 200lb lean athlete on 4 to 9mg retatrutide for 16 weeks, realistic expectations:

• 8 to 14lbs of total body weight loss
• 4 to 6lbs of fat (best case)
• 4 to 8lbs of lean tissue, of which probably 2 to 4lbs is skeletal muscle

That is on top of the muscle preservation work the trials never measured: protein at 2.3 to 3.1g/kg lean body mass (Helms et al., 2014), resistance training volume held constant, and weight loss rate kept at 0.5 to 1.0% of body weight per week, the threshold above which lean mass preservation breaks down in trained athletes (Garthe et al., 2011). Garthe's elite-athlete study is worth flagging because it ran fast (1.4%/week) versus slow (0.7%/week) weight loss with matched protein intake and matched training. The slow group gained 2.1% lean mass and improved 1RM strength. The fast group lost 0.2% lean and didn't improve strength. Same total weight lost, different composition.

The retatrutide 12mg arm produces roughly 0.35%/week sustained over 80 weeks, which sits comfortably under Garthe's threshold for obese subjects. For a lean athlete who hits 1% of body weight per week early on (water and glycogen drop fast), the effective rate may push above the lean-preservation envelope unless protein and training are aggressive.

The dysesthesia and heart rate signal

Two safety signals in TRIUMPH-1 changed how the bodybuilding community should think about pushing dose. Dysesthesia, an abnormal skin sensitivity often described as burning or tingling, showed a clear dose-response: 5.1% at 4mg, 12.3% at 9mg, 12.5% at 12mg, versus 0.9% on placebo. Phase 2 didn't flag this clearly. The companion TRIUMPH-4 trial in knee osteoarthritis reported a 20.9% rate at 12mg, which suggests cohort and duration sensitivity. Most cases are mild to moderate and resolve during treatment, but the signal is real and you should know to expect it.

The heart rate signal is more important for stacking. TRIUMPH-1 hasn't published exact bpm numbers in its topline release, but Phase 2 showed roughly +5 to +7bpm at the 8 and 12mg doses, peaking around week 24 before partially declining (Jastreboff et al., 2023). A network meta-analysis of GLP-1 agonist HR effects (Zhang et al., 2026) put retatrutide's pooled HR delta at +3.46bpm versus placebo, comparable to oral semaglutide and lower than orforglipron.

The mechanism matters here. Retatrutide's third agonism, the glucagon receptor, drives hepatic futile cycling and raises basal metabolic rate (Conceição-Furber et al., 2022). This is part of why it produces more weight loss than tirzepatide or semaglutide. It is also why it runs the engine hotter at the same body weight. The HR rise and the BMR increase are coupled. You don't get one without the other.

Stacking implications you actually need to read

For a clean enhanced athlete on TRT, +5 to +7bpm baseline is tolerable. The problem is what you're stacking on top.

Stimulant pre-workouts add 3 to 7bpm acutely at 200 to 400mg caffeine. Layered on retatrutide, your working HR during cardio is meaningfully higher than baseline. Cut pre-workout dose or skip it on cardio days.

Clenbuterol is the worst combination on this list. Beta-2 agonist tachycardia, electrolyte shifts (hypokalemia), arrhythmia case reports even at low doses (Spiller et al., 2013). Adding retatrutide's GI losses (potassium dropping further from diarrhoea) and chronic HR baseline rise creates real arrhythmia risk. Don't run both simultaneously.

T3 above 50mcg/day stacked with retatrutide is additive chronotropic and thermogenic load. It's a cardiovascular bet that nobody has data on.

Trenbolone already raises resting BP and HR, with documented endothelial dysfunction and MI case reports in young users (Frati et al., 2015). Stacking with retatrutide layers two independent cardiac stressors without any clinical data on the combination.

DNP: do not stack. Period. The combination of glucagon-driven BMR rise plus uncoupling protein activation is a hyperthermia setup.

The cleaner play is to sequence rather than overlap. Run retatrutide as the primary cutting tool, hold the harsh compounds for the back half of prep after retatrutide is held or dropped, and don't try to push two thermogenic systems at once.

Should you drop your test dose? A 4-question decision tree

Forum lore says you should cruise lower on retatrutide. The clinical evidence does not support that. Here is the actual framework based on what happens to your endocrine profile during rapid weight loss.

Question 1: Are you in surplus, maintenance, or deficit?

In surplus or maintenance, leave the test dose alone. There is no mechanistic reason to drop. In aggressive deficit (more than 500 kcal/day below maintenance), hold the dose constant but watch recovery and libido markers because SHBG will rise (Camacho et al., 2013; Corona et al., 2013), which means your free testosterone fraction will fall at the same total testosterone.

Question 2: What's your baseline SHBG?

If SHBG is already low (common in lean AAS users running aromatisable compounds), a modest rise during weight loss is unlikely to push free T into a symptomatic range. If SHBG is high at baseline (above 50 nmol/L, which happens on anavar-free or natural TRT regimens), the rise during weight loss can produce real symptoms. That argues against any dose reduction, not for one.

Question 3: Where is your estradiol?

Adipose tissue is the dominant peripheral site of aromatisation. As you drop fat mass, aromatisation decreases. E2 may drift down at the same test dose. Don't pre-emptively drop test to control E2. Retest E2 at week 6 to 8 of meaningful weight loss and adjust your aromatase inhibitor (if any) rather than your testosterone dose.

Question 4: Are you symptomatic?

Libido drop, mood crash, recovery decline, and persistent fatigue at week 6 to 8 of retatrutide usually point to low energy availability suppressing the HPG axis (Areta et al., 2021) layered on top of TRT. The solution is almost always more food, cyclical refeeds, and possibly HCG for testicular tone. Cutting test dose makes the recovery problem worse.

The summary: stable test dose, watch SHBG and E2, refeed when symptomatic. The "cruise lower on reta" advice is not what the physiology suggests.

Retatrutide vs tirzepatide vs semaglutide: the cross-trial picture

There is no head-to-head trial. SURMOUNT-5 ran tirzepatide vs semaglutide directly, but no comparable retatrutide head-to-head exists or is planned in the near term. Cross-trial comparisons exaggerate differences because trial duration, baseline BMI, placebo run-in, and lifestyle support all vary. With that caveat:

The standout retatrutide-specific finding is the hepatic fat clearance from the Phase 2a MASLD trial (Sanyal et al., 2024): about 82% relative liver fat reduction at 8mg and 12mg in subjects with baseline liver fat ≥10%, with around 90% achieving complete steatosis resolution. SYNERGY-NASH put tirzepatide's MASH resolution at around 62% at 15mg (Loomba et al., 2024). Semaglutide's ESSENCE trial sits at around 63% MASH resolution.

For an enhanced athlete using orals, this matters more than it does for an obese patient. Dianabol, anadrol, and high-dose anavar all push liver fat and transaminases. If you're running orals through a cut, retatrutide's hepatic effects probably outweigh tirzepatide's in terms of liver-specific benefit. That's a separate conversation from weight loss magnitude.

Why retatrutide loses more weight (and runs hotter)

The mechanism: glucagon receptor activation stimulates hepatic glucose production and fatty acid oxidation, raises basal metabolic rate via FGF21 and uncoupling protein 1 activation, and adds to the satiety effects of GLP-1 and GIP (Conceição-Furber et al., 2022). Without GIP and GLP-1's opposing glucose-lowering effects, glucagon alone would worsen glycaemia. Together, the three signals produce the strongest metabolic shift the class has achieved.

That same glucagon arm is what raises heart rate more than tirzepatide. You don't get the muscle-burning fat without the cardiac strain. They are mechanistically yoked.

Bloodwork by week, mapped to TRIUMPH-1 safety signals

This is the panel I'd run for a TRT-supported athlete on retatrutide, with the trigger logic tied to specific TRIUMPH-1 and Phase 2 findings. For full baseline panel and ongoing surveillance schedule, see Retatrutide Bloodwork: The Triple Agonist Monitoring Guide. The week-by-week breakdown below is the narrower TRIUMPH-1-derived overlay.

Week 4 panel (early tolerability)

• Lipase + amylase: catch asymptomatic pancreatic enzyme rises. Phase 2 noted one acute pancreatitis case in the 12mg arm. Class-wide pancreatitis risk in the latest meta-analysis (Wen et al., 2025) shows a modest signal (RR 1.44, 95% CI 1.09 to 1.89) that attenuates to non-significance in subgroups using concomitant antidiabetic medication. Enzyme rises are common and usually silent, but the pancreatitis signal is real enough to flag.
• ALT, AST: rapid hepatic fat mobilisation can transiently bump transaminases.
• Creatinine + eGFR: GI losses from nausea and diarrhoea raise prerenal dehydration risk.
• Resting HR + BP at clinic and from a wearable: Phase 2 HR peak hit at week 24, so week 4 is your trajectory check.

Triggers: Lipase above 3× upper limit with abdominal pain, stop and image. HR sustained above 100 or 15+ above personal baseline, hold dose escalation and retest in 4 weeks.

Week 12 panel (metabolic trajectory)

• Fasting glucose, insulin, calculated HOMA-IR, HbA1c: confirms the drug is engaging the GLP-1 and GIP axis. HOMA-IR should drop meaningfully (often from 2.5+ to 1.5 range) if the dose is working.
• Lipid panel: triglycerides will drop dramatically. LDL-C may transiently rise during active fat mobilisation, which is a known artifact of weight loss and not a sign retatrutide is harming you.
• TSH only if symptomatic (cold intolerance, hair shedding, persistent fatigue). Caloric restriction can drop free T3 even with normal TSH.

Triggers: HbA1c flat and weight flat after 12 weeks of titration, dose is subtherapeutic, escalate or reassess sourcing quality. Resting HR still elevated, continue dose hold.

Week 24 panel (the honest readout)

• Full lipid panel + ApoB: ApoB is the load-bearing marker during weight loss. Sniderman's meta-analysis showed ApoB predicts cardiovascular events about 12% better than LDL-C (Sniderman et al., 2011), and the LDL-C/ApoB discordance gets larger during active fat mobilisation. If LDL-C is up but ApoB is down, you're fine. If both are up, audit dietary saturated fat.
• Repeat HbA1c and lipase/amylase.
• Liver panel: ALT, AST, GGT, total bilirubin. Hepatic ultrasound or FibroScan if you have access, given the Phase 2a MASLD data on hepatic fat clearance.

Triggers: ApoB rising despite weight loss, check dietary saturated fat and reassess intake. eGFR drop >20% from baseline, hydration audit and clinician review.

The micro-dose recomp protocol (caveat heavy)

This section needs to be read carefully because the gap between forum practice and clinical evidence is wide. TRIUMPH-1 used 4mg, 9mg, and 12mg dose arms. The 1mg and 2mg doses that circulate in PED forums as "recomp doses" were Phase 2 only and produced about −8.7% body weight over 48 weeks in obese subjects (Jastreboff et al., 2023). There is no Phase 3 validation of sub-therapeutic dosing in lean athletes.

The theoretical case for micro-dose retatrutide as a recomp tool rests on three observations:

1. Lower dose means lower weight loss velocity, which keeps you closer to Garthe's 0.7%/week lean-preservation envelope (Garthe et al., 2011).
2. GI side effect rates at 1mg in Phase 2 were roughly 3 to 4× lower than at 12mg, which means fewer GI losses and better adherence to protein intake.
3. The HR rise at 1mg was smaller and may not trigger meaningful cardiac stack concerns with stimulants or TRT.

The case against:

1. Zero clinical validation in lean populations. The dose-response curve in obese subjects may not translate.
2. Counterfeit and underdosed product risk is highest in the retatrutide grey market right now. A "2mg" injection from an unvetted vendor could be anywhere from 0mg to 5mg.
3. Even at 1mg, pancreatitis risk is idiosyncratic, not dose-linear. Bloodwork cadence at micro-dose should still be week 4, 12, and 24.

The Longland protocol gives the playbook for muscle preservation in any caloric deficit (Longland et al., 2016): 2.4g protein per kg total body weight (closer to 3.0g per kg lean body mass), resistance training volume held constant, 40% deficit tolerable with these inputs. Longland produced +1.2kg lean body mass gain with −4.8kg fat loss over 4 weeks in young men. That study had no GLP-1 drug. Adding retatrutide at micro-dose is theoretically additive to the fat loss side of the equation. Nobody has proven it.

The harm-reduction summary: if you're going to do this anyway, run a real lab panel, eat the protein, lift the same weights you were lifting before, and keep weight loss under 1% of body weight per week.

What this means for FDA approval and access

TRIUMPH-1 is the pivotal Phase 3 trial Eli Lilly needed for an obesity indication. Combined with TRIUMPH-4 (knee osteoarthritis, already topline positive) and the still-reading TRIUMPH-2 (T2D) and TRIUMPH-3 (cardiovascular outcomes), retatrutide is on track for FDA submission in late 2026 with potential approval in late 2027 if no surprises emerge from the cardiovascular outcomes trial.

What that means for grey-market access right now:

• Compounding pharmacies that produce retatrutide in jurisdictions that allow it (some US states, parts of Asia) are operating on uncertain legal ground. The FDA could remove compounding eligibility for retatrutide at any point.
• Research peptide vendors continue to sell retatrutide as "for research use only." Quality and purity are uncontrolled. Without third-party HPLC validation, you have no idea what's in the vial.
• Expect retatrutide brand-name product to launch at semaglutide-like pricing (around USD $1,000+/month list price) when approved. Insurance coverage will lag and will likely be restricted to BMI ≥30 with comorbidities, mirroring Zepbound and Wegovy coverage policies.

The athletes who will end up on retatrutide first are not the obese trial population. They're TRT-supported lifters, contest preppers, and recomp users sourcing through grey channels. The clinical data answers their questions only obliquely. This article tried to bridge that gap.

Key takeaways

• TRIUMPH-1 showed 28.3% mean weight loss at 12mg retatrutide over 80 weeks, climbing to 30.3% in the BMI ≥35 extension cohort at 104 weeks.
• No TRIUMPH-1 DEXA substudy is published yet. The best benchmark for lean mass loss is SURMOUNT-1's 75% fat / 25% lean ratio, applied with caveats because obese trial subjects had more fat to lose than a lean athlete does.
• An athlete at 12% body fat targeting 28% total weight loss would liquidate their physique. Realistic targets for a 16-week cut at 4 to 9mg are 8 to 14lbs total, with proportionally higher muscle loss than the trials report.
• Dysesthesia rates hit 12.5% at 12mg, and the dose-dependent +5 to 10bpm HR rise interacts badly with clen, T3, tren, and high-dose stimulants. Sequence rather than stack.
• Don't pre-emptively drop test dose. SHBG rises during weight loss, E2 may drift down, and the symptomatic answer is usually more food, not less testosterone.
• Bloodwork at week 4 (lipase, creatinine, HR), week 12 (insulin, HOMA-IR, lipids), and week 24 (ApoB, full liver panel) catches the TRIUMPH-1 safety signals before they become problems.
• Micro-dose 1 to 2mg recomp protocols are Phase 2 extrapolations with zero Phase 3 validation in lean athletes. Counterfeit risk is the dominant safety concern, not the dosing math.

---

References

1. Eli Lilly and Company. (2026, May 21). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial [Press release]. PR Newswire

2. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PubMed

3. Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529-544. PubMed

4. Coskun, T., Wu, Q., Schloot, N. C., Heertum, S. V., Hartman, M. L., Haupt, A., & Milicevic, Z. (2025). Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684. PubMed

5. Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 27(5), 2720-2729. PubMed

6. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. PubMed

7. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. PubMed

8. Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037-2048. PubMed

9. Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. New England Journal of Medicine, 391(4), 299-310. PubMed

10. Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017). Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology, 16(1), 6. PubMed

11. Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022). Is glucagon receptor activation the thermogenic solution for treating obesity? Frontiers in Endocrinology, 13, 868037. PMC

12. Camacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Tajar, A., et al. (2013). Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. European Journal of Endocrinology, 168(3), 445-455. PubMed

13. Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. European Journal of Endocrinology, 168(6), 829-843. PubMed

14. Areta, J. L., Taylor, H. L., & Koehler, K. (2021). Low energy availability: history, definition and evidence of its endocrine, metabolic and physiological effects in prospective studies in females and males. European Journal of Applied Physiology, 121, 1-21. PubMed

15. Spiller, H. A., James, K. J., Scholzen, S., & Borys, D. J. (2013). A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Substance Abuse, 34(3), 306-312. PubMed

16. Frati, P., Busardo, F. P., Cipolloni, L., De Dominicis, E., & Fineschi, V. (2015). Anabolic-androgenic steroid (AAS) related deaths: autoptic, histopathological and toxicological findings. Current Neuropharmacology, 13(1), 146-159. PubMed

17. Wen, J., et al. (2025). Evaluating the rates of pancreatitis and pancreatic cancer among GLP-1 receptor agonists: a systematic review and meta-analysis of randomised controlled trials. Endocrinology, Diabetes & Metabolism. PMC

18. Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011). A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circulation: Cardiovascular Quality and Outcomes, 4(3), 337-345. PubMed

19. Longland, T. M., Oikawa, S. Y., Mitchell, C. J., Devries, M. C., & Phillips, S. M. (2016). Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. American Journal of Clinical Nutrition, 103(3), 738-746. PubMed

20. Garthe, I., Raastad, T., Refsnes, P. E., Koivisto, A., & Sundgot-Borgen, J. (2011). Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. International Journal of Sport Nutrition and Exercise Metabolism, 21(2), 97-104. PubMed

21. Helms, E. R., Aragon, A. A., & Fitschen, P. J. (2014). Evidence-based recommendations for natural bodybuilding contest preparation: nutrition and supplementation. Journal of the International Society of Sports Nutrition, 11, 20. PubMed